Genesystem Co Ltd

XKRX:363250 (Korea (the Republic of))  
â‚© 6450.00 (+7.32%) May 27
At Loss
P/B:
1.78
Market Cap:
â‚© 45.05B ($ 33.21M)
Enterprise V:
â‚© 35.19B ($ 25.94M)
Volume:
66.14K
Avg Vol (2M):
153.25K
Volume:
66.14K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Genesystem Co Ltd ( XKRX:363250 ) from 2021 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Genesystem stock (XKRX:363250) PE ratio as of May 28 2024 is 0. More Details

Genesystem Co Ltd (XKRX:363250) PE Ratio (TTM) Chart

To

Genesystem Co Ltd (XKRX:363250) PE Ratio (TTM) Historical Data

Total 769
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 9
Genesystem PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-27 At Loss 2024-03-19 At Loss
2024-05-24 At Loss 2024-03-18 At Loss
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-08 At Loss
2024-04-16 At Loss 2024-02-07 At Loss
2024-04-15 At Loss 2024-02-06 At Loss
2024-04-12 At Loss 2024-02-05 At Loss
2024-04-11 At Loss 2024-02-02 At Loss
2024-04-09 At Loss 2024-02-01 At Loss
2024-04-08 At Loss 2024-01-31 At Loss
2024-04-05 At Loss 2024-01-30 At Loss
2024-04-04 At Loss 2024-01-29 At Loss
2024-04-03 At Loss 2024-01-26 At Loss
2024-04-02 At Loss 2024-01-25 At Loss
2024-04-01 At Loss 2024-01-24 At Loss
2024-03-29 At Loss 2024-01-23 At Loss
2024-03-28 At Loss 2024-01-22 At Loss
2024-03-27 At Loss 2024-01-19 At Loss
2024-03-26 At Loss 2024-01-18 At Loss
2024-03-25 At Loss 2024-01-17 At Loss
2024-03-22 At Loss 2024-01-16 At Loss
2024-03-21 At Loss 2024-01-15 At Loss

Genesystem Co Ltd (XKRX:363250) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.